RxDoctor Payments Data

Brady Simonak, DO

Family Medicine · Fort Worth, TXNPI 1821418658

Payments from drug & device makers

$9,911in general payments, 2019–2025

Across 621 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$801
  • Boehringer Ingelheim$713
  • Abbott$682
  • AstraZeneca$657
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$598
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$9,911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)115$1,583
Lilly USA, LLC57$801
Boehringer Ingelheim43$713
Abbott32$682
AstraZeneca41$657
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$598
Pfizer34$575
GSK26$467
Novo Nordisk28$393
Bayer22$355
Amgen(2 entities)22$336
Kowa Pharmaceuticals America, Inc.15$214
Amarin Pharma, Inc.9$173
Avvisto Therapeutics, LLC10$160
Biohaven Pharmaceutical Holding Company Ltd.8$152
Endo Pharmaceuticals Inc.9$149
Astellas Pharma US Inc8$140
Merck9$122
Corium, LLC4$107
Genentech USA, Inc.6$89
Takeda Pharmaceuticals U.S.A., Inc.5$80
Ironshore Pharmaceuticals Inc.4$75
Acella Pharmaceuticals, LLC4$75
Otsuka America Pharmaceutical, Inc.4$64
Currax Pharmaceuticals LLC5$64
Eisai Inc.3$62
Exact Sciences3$60
Sanofi-aventis U.S. LLC4$60
IBSA Pharma Inc.3$58
Johnson & Johnson4$58
Sanofi Pasteur Inc.3$53
Supernus Pharmaceuticals, Inc.3$48
Gilead3$44
Kaleo, Inc.3$43
Teva Pharmaceuticals USA, Inc.3$43
Shire North American Group Inc3$43
Azurity Pharmaceuticals, Inc.3$42
Novartis3$39
Biohaven Pharmaceuticals, Inc.2$37
Tris Pharma Inc2$34
Esperion Therapeutics, Inc.2$31
Althera Pharmaceuticals LLC2$28
Axsome Therapeutics, Inc.1$27
Idorsia Pharmaceuticals US Inc2$27
Amneal Pharmaceuticals LLC1$24
Nevro Corp.1$23
Optinose US, Inc.1$21
Nestle Healthcare Nutrition Inc.1$21
Bioventus LLC1$18
Medtronic1$17
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Adlon Therapeutics L.p.1$15
Silk Road Medical, Inc.1$15
Arbor Pharmaceuticals, Inc.1$15
Halozyme Inc1$14
Mannkind Corporation1$14
Seqirus USA Inc1$13
Galderma Laboratories, L.p.1$12
Paratek Pharmaceuticals, Inc.1$12

How this compares

$9,911 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,091
Medicare patients
210
Services billed
22,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$98,133
OzempicSemaglutide66$82,440
MounjaroTirzepatide32$64,692
RybelsusSemaglutide15$25,167
EliquisApixaban15$25,158
VraylarCariprazine Hcl16$25,118
UbrelvyUbrogepant11$18,655
FarxigaDapagliflozin Propanediol12$18,563
TrulicityDulaglutide15$18,015
JanuviaSitagliptin Phosphate20$16,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$14,520
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,980
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$5,546
UnithroidLevothyroxine Sodium89$5,513
Liothyronine Sodium101$3,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$393$107,60781 claims
Boehringer IngelheimJardiance$713$98,13392 claims
Lilly USA, LLCMounjaro, Trulicity$801$82,70747 claims
AbbVieVraylar, Ubrelvy, Synthroid$1,583$45,22342 claims
PfizerEliquis$575$25,15815 claims
GSKTrelegy Ellipta, Anoro Ellipta$467$22,49923 claims
AstraZenecaFarxiga$657$18,56312 claims
MerckJanuvia$122$16,39320 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$24$6,940288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →